Molecular mechanisms of bone metastasis

Cancer Genomics and Proteomics

Volumn 13, Issue 1, 2016, Pages 1-12

  Weidle, Ulrich H ^a   Birzele, Fabian ^a   Kollmorgen, Gwendlyn ^a   Rüger, Rüdiger ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Bisphosphonates; Bone tropism of metastasis; Denosumab; Genes mediating and modulating bone metastasis; Preand metastatic niche(s); Review; Vicious cycle

Indexed keywords

ALENDRONIC ACID; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; CLODRONIC ACID; DASATINIB; DENOSUMAB; ETIDRONIC ACID; GLYCOPROTEIN; IBANDRONIC ACID; LENALIDOMIDE; MICRORNA; MONOCLONAL ANTIBODY; ODANACATIB; PAMIDRONIC ACID; PHOSPHOPROTEIN; POMALIDOMIDE; PROTEASOME INHIBITOR; SARACATINIB; SMALL INTEGRIN BINDING N LINKED GLYCOPROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE METASTASIS; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TROPISM; TUMOR CELL; VALIDATION STUDY; ANIMAL; BONE TUMOR; BREAST TUMOR; FEMALE; GENETICS; MALE; METABOLISM; METASTASIS; MULTIPLE MYELOMA; PATHOLOGY; PROSTATE TUMOR; SECONDARY;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 84959363249     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Langley RR and Fidler IJ: The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128:2527-2535, 2011.
2. Jacofsky DJ, Frassica DA and Frassica FJ: Metastatic disease to bone. Hospital Physician 40:21-28, 2004.
3. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenz R and Abbruzzese JL: Metastatic patterns in adenocarcinoma: Cancer 106:1624-1633, 2006.
4. Kraljevic-Pavelic S, Sedik M, Bosnjak H, Spaventi S and Pavelic K: Metastasis: new perspectives of an old problem. Mol Cancer 10:22, 2011.
5. Guise TA: The vicious cycle of bone metastasis. J Musculoskelet Interact 2:570-572, 2002.
6. Rodman GD: Mechanisms of bone metastasis. N Engl J Med 350:1655-1664, 2004.
7. Nguyen DX, Bos PD, Massaggue J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274-284, 2009.
8. Saki N, Abroun S, Farshdoushi Hagh M and Asgharei F: Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J 13:131-136, 2011.
9. Gupta GP and Massague J: Cancer metastasis: building a framework. Cell 127:679-695, 2006.
10. Chiang AC and Massague J: Molecular basis of metastasis. N Engl J Med 359:2814-2823, 2008.
11. Azizidoost S, Babashah S, Rahim F, Shahjahani M and Saki N: Bone marrow neoplastic niche in leukemia. Hematology 19:232-238, 2014.
12. Giancotti FG: Mechanisms governing metastatic dormancy and reactivation. Cell 155:750-764, 2013.
13. Theriault RL: Biology of bone metastasis. Cancer Control 19:92-101, 2012
14. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593, 2002.
15. Dougall WC: Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18:326-335, 2012.
16. Dougall WC, Holen I and Gonzalez Suarez E: Targeting RANKL in metastasis. Bonekey Rep 3:519, 2014.
17. Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna A, Teti A, Angelucci A and Dolo V: Receptor activator of NF-kappaB ligand enhances breasr cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res 70:6150-6160, 2010.
18. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA and Karin M: Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing maspin. Nature 446:690-694, 2007.
19. Ferrari-Lacraz S and Ferrari S: Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporosis Int 22:435-446, 2011.
20. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM and Beissert S: Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12:1372-1379, 2006.
21. Soki FN, Park SI, McCauley LK: The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol 8:803-817, 2012.
22. Rucci N, Sanita P, Delle Monache S, Alesse E and Angelucci A: Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets. World J Clin Oncol 5:335-347, 2014.
23. Wang Y, Lei R, Zhuang X, Zhang N, Pan H, Li G, Hu J, Pan X, Tao Q, Fu D, Xiao J, Chin YW, Kang Y, Yang Q and Hu G: DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis. J Clin Invest 124:1646-1659, 2014.
24. Roato I: Bone metastases: When and how lung cancer interacts with bone. World J Clin Oncol 10:149-155, 2014.
25. Ye L, Kynaston HG and Jiang WG: Bone metastasis in prostate cancer: molecular and cellular mechanisms. Int J Mol Med 20:103-111, 2007.
26. Nandana S and Chung LW: Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol 12:92-101, 2014.
27. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ and Lin SH: Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6:1259-1267, 2008.
28. Rahim F, Hajizamani S, Mortaz E, Ahmadzadeh A, Shahjahani M, Shahrabi S and Saki N: Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res 2014:405620, 2014.
29. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20:287-296, 2001.
30. Buenrostro D, Park SI and Sterling JA: Dissecting the role of bone marrow stromal cells on bone metastasis. Biomed Res Int 2014:875305, 2014.
31. Cramer SD, Chen Z and Peehl DM: Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156:526-531, 1996.
32. Kaplan RN, Psaila B and Lyden D: Bone marrow cells in the "pre-metastatic niche": within bone and beyond. Cancer Metastasis Rev 25:521-529, 2006.
33. Peinado H, Lavotshkin S and Lyden D: The secreted factors for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21:139-146, 2011.
34. Barcellos-Hoff MH, Lyden D and Wang TC: The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 13:511-518, 2013.
35. Psaila B and Lyden D: The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9:285-293, 2009.
36. Wang H, Yu C, Gao X, Welte T, Muscarella AM, Tian L, Zhao H, Zhaho Z, Du S, Tao J, Lee B, Westbrook TF, Wong ST, Yin X, Rosen JM, Osborne CK and Zhang XH: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27:193-210, 2015.
37. Tinoco G, Warsch S, Glück S, Avancha K and Montero AJ: Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 4:117-132, 2013.
38. Johnston SR: New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16:1979-1987, 2010.
39. Cox TR, Rumney RM, Schoof EM, Perryman L, Hoye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A and Erler JT: The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522:106-110, 2015.
40. Keller ET, Dai J, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS and Keller J: New trends in the treatment of bone metastasis. J Cell Biochem 102:1095-1102, 2007.
41. Thery C, Zitvogel L and Amigorena S: Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569-579, 2002.
42. Henderson MC and Azorsa DO: The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol 2:38, 2012.
43. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan Y, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J and Lyden D: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through EMT. Nat Med 18:883-891, 2012.
44. Pantel K, Brakenhoff RH and Brandt B: Detection, clinical relevance and specific biological properties of disseminated tumor cells. Nat Rev Cancer 8:329-340, 2008.
45. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834-846, 2007.
46. Alix-Panabieres C, Riethdorf S and Pantel K: Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 14:5013-5021, 2008.
47. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behaviour of breast cancer subtypes. J Clin Oncol 28:3271-3277, 2010.
48. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA and Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114, 2008.
49. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS: Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109:2784-2789, 2012.
50. Brabletz T: To differentiate or not-routes towards metastasis. Nat Rev Cancer 12:425-436, 2012.
51. Chaffer CL and Weinberg RA: A perspective of cancer cell metastasis. Science 331:1559-1564, 2011.
52. Francia G, Cruz-Munoz W, Man S, Xu P and Kerbel RS: Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 11:135-141, 2011.
53. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA and Massague: Latent bone metastasis in breast cancer tied to Src-dependant survival signals. Cancer Cell 16:67-78, 2009.
54. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA and Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549, 2003.
55. Sethi N, Dai X, Winter CG and Kang Y: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer cells by engaging notch signalling in bone cells. Cancer Cell 19:192-205, 2011.
56. Lu X, Mu E, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massague J and Kang Y: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 20:701-714, 2011.
57. Campbell JP, Karolak MR, Ma Y, Perrien DS, Masod-Campbell SK, Penner NL, Munoz SA, Zijlstra A, Yang X, Sterling JA and Elefteriou F: Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 10:e1001363, 2012.
58. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC and Aguirre-Ghiso JA: ERK1/2 and p38α/β in tumor quiescence: opportunities to control dormant residual disease. Clin Cancer Res 17:5850-5857, 2011.
59. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212-216, 2008.
60. Adwan H, Bäuerle TJ and Berger MR: Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 11:109-120, 2004.
61. Bäuerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP and Berger MR: Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115:177-186, 2005.
62. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT and Noda M: Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Mineral Res 16:652-659, 2001.
63. Weichhaus M, Chung ST and Connelly L: Osteoprotogerin in breast cancer: beyond bone remodelling. Mol Cancer 14:117, 2015.
64. Zhang JH, Wang J, Tang J, Barnett B, Dickson J, Hashimoto N, Williams P, Ma W, Zheng W, Yoneda T, Pageau S and Chen J: Bone sialoprotein promotes bone metastasis of a non-boneseeking clone of human breast cancer cells. Anticancer Res 24:1361-1368, 2004.
65. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS and MacCauley LK: Use of stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832-1837, 2002.
66. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174, 2002.
67. Zhao W, Byrne MH, Boyce BF and Krane SM: Bone resorption induced by parathyroid hormone is strikingly diminished in collgenase-resistant mutant mice. J Clin Invest 103:517-524, 1999.
68. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O and Hammond HK: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2:534-539, 1996.
69. Moussad EE and Brigstock DR: Connective tissue growth factor: what's in a name? Mol Genet Metab 71:276-292, 2000.
70. Manolagas SC: Role of cytokines in bone resorption. Bone 17:63S-67S, 1995.
71. van't Veer, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002.
72. Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, Wang QS and Feng YM: ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGF-β signalling pathway. Cancer Res 75:3302-3313, 2015.
73. Berg RW, Leung E, Gough S, Morris C, Yao WP, Wang SX, Ni J and Krissansen GW: Cloning and characterization of a novel beta integrin-related cDNA coding for the protein TIED ("ten beta integrin EGF-like repeat domains") that maps to chromosome band 13q33: A divergent stand-alone integrin stalk structure. Genomics 56:169-178, 1999.
74. Fournier PG, Juarez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM and Guise TA: The TGF-βsignaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell 27:809-821, 2015.
75. Wang J, Loberg R and Taichman RS: The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 25:573-587, 2006.
76. Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107:1761-1767, 2006.
77. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK and Taichman RS: Skeletal localization and neutralization of SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20:318-329, 2005.
78. Houshmand P and Zlotnik A: Targeting tumor cells. Curr Opin Cell Biol 15:640-644, 2003.
79. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ and Taichman RS: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancer (PCa) in vivo. J Cell Biochem 89:462-473, 2003.
80. Engl T, Relia B, Marian D, Blumenberg C, Müller I, Beeken WD, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D and Blaheta RA: CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 8:290-301, 2006.
81. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ and Taichman RS: Expression and activation of alpa v beta 3 integrins by SDF1/CXCL12 increases the aggressiveness of prostate cancer cells. Prostate 67:61-73, 2007.
82. Havens AM, Jung Y, Sun YX, Wang J, Shah RB, Bühring HJ, Pienta KJ and Taichman RS: The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer 6:195, 2006.
83. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD and Cher ML: CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of the bone microenvironment-associated CXCL12. Prostate 66:32-48, 2006.
84. Wang J, Wang J, Sun Y, Song W, Nor JE, Wang CY and Taichman RS: Diverse signalling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 17:1578-1592, 2005.
85. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE and Price JE: CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65:6493-6497, 2005.
86. Jansson MD and Lund AH: MicroRNA and cancer. Mol Oncol 6:590-610, 2012.
87. Croset M, Santini D, Juliani M, Fioramonti M, Zoccoli A, Vincenzi B, Tonini G and Pantano F: Micro RNAs and bone metastasis: a new challenge. Molecules 19:10115-10128, 2014.
88. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y and Dahiya R: Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 17:5287-5298, 2011.
89. Bellahcene A, Bachelier R, Detry C, Lidereau R, Clezardin P and Castronovo V: Transcriptome analysis reveals an osteoblastlike phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 101:135-148, 2007.
90. Le Gall C, Bellahcene A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J and Clezardin P: A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 67:9894-9902, 2007.
91. Tin J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y and Fan D: MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6:e10000879, 2010.
92. Croset M, Bachelier R, Allioli N, Song SS, Agami R and Clezardin P: Targeting breast cancer osteomimetic genes by microRNAs-30 decreases the formation of metastatic osteolytic lesions in mice. Bull Cancer 98:S29-S30, 2011.
93. Wu T, Zhou H, Hong Y, Li J, Jiang X and Huang H: MiR-30 family members negatively regulate osteoblast differentiation. J Biol Chem 287:7503-7511, 2012.
94. Kuo PL, Liao SH, Hung JY, Huang MS and Hsu YL: MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta 1830:3756-3766, 2013.
95. Bouchie A: First microRNA mimic enters clinic. Nat Biotechnol 31:577, 2013.
96. Li BT, Wong MH and Pavlakis N: Treatment and prevention of bone metastasis from breast cancer: A comprehensive review of evidence for clinical practice. J Clin Med 3:1-24, 2014.
97. Wong M and Pavlakis N: Optimal management of bone metastases in breast cancer patients. Breast Cancer 3:35-60, 2011.
98. Frith JC, Mönkkönen J, Auriola S, Mönkkönen H and Rogers MJ: The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodrante: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201-2210, 2001.
99. Russell RG: Bisphosphonates: the first 40 years. Bone 49:2-19, 2011.
100. Erdogan B and Cicin I: Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs. Asian Pac J Cancer Prev 15:1503-1510, 2014.
101. Lipton A: Denosumab in breast cancer. Curr Oncol Rep 13:1-4, 2011.
102. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichnitser M, Fujiwara Y, Yardley DA, Vaniegra M, Fan M, Jiang Q, Dansey R, Jun. S and Braun A: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J Clin Oncol 28:5132-5139, 2010.
103. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J and Cook R: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935, 2005.
104. Hiscox S, Barrett-Lee P, Borley AC and Nicholson RI: Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer 46:2187-2195, 2010.
105. Hannon RA, Finkelman RD, Clack G, Iacona RB, Rimmer M, Gossiel F, Baselga J and Easell R: Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. Bone 50:885-892, 2012.
106. Watanabe R and Okazaki R: Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis. Clin Calcium 24:59-67, 2014.
107. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Misiades C, Prabhala R, Raje N, Anderson KC, Stover DR and Munshi NC: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371-379, 2009.
108. Hameed A, Brady JJ, Dowling P, Clynes M and O'Gorman P: Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis 10:33-42, 2014.
109. Katz LH, Li Y, Chen JS, Munoz NM, Majumdar A, Chen J and Mishra L: Targeting TGF-β signalling in cancer. Exp Opin Ther Targets 17:743-760, 2013.
110. Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE and Spiegelman B: Tumor-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513:100-104, 2014.